Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 76.94%51.36M | 36.75%32.26M | -0.37%24.88M | -24.17%111.65M | 1.94%34.06M | -14.50%29.03M | -44.49%23.59M | -33.17%24.97M | -9.18%147.23M | -14.64%33.41M |
| Operating revenue | 76.94%51.36M | 36.75%32.26M | -0.37%24.88M | -24.17%111.65M | 1.94%34.06M | -14.50%29.03M | -44.49%23.59M | -33.17%24.97M | -9.18%147.23M | -14.64%33.41M |
| Cost of revenue | 58.87%36.59M | 11.96%21.77M | 5.32%19.47M | -32.54%86.01M | -16.26%25.05M | -13.43%23.03M | -49.72%19.44M | -42.77%18.49M | -5.85%127.5M | -20.43%29.91M |
| Gross profit | 146.31%14.77M | 152.93%10.49M | -16.62%5.4M | 29.93%25.63M | 157.78%9.01M | -18.39%6M | 8.30%4.15M | 28.16%6.48M | -26.06%19.73M | 126.30%3.49M |
| Operating expense | -13.70%14.17M | -0.71%14.63M | -33.65%11.07M | -21.77%63.73M | 16.59%15.89M | -23.76%16.42M | -82.79%14.73M | 5.56%16.69M | 20.11%81.47M | -56.28%13.63M |
| Selling and administrative expenses | -16.42%13.98M | -3.74%14.3M | 3.43%17.18M | -11.31%66.8M | 34.46%18.6M | -19.24%16.73M | -41.88%14.86M | 9.28%16.61M | 23.35%75.31M | -46.08%13.84M |
| Research and development costs | 312.90%264K | 169.35%536K | -92.18%24K | -114.98%-290K | -358.46%-672K | -226.53%-124K | -77.56%199K | -55.57%307K | -25.80%1.94M | -77.13%260K |
| Provision for doubtful accounts | ---- | ---- | ---- | --0 | --0 | --0 | --0 | ---- | 31.64%5.67M | -87.48%539K |
| Other operating expenses | 60.44%-72K | 35.06%-213K | -2,635.27%-6.13M | -92.04%-2.78M | -102.88%-2.04M | -34.81%-182K | -44.49%-328K | -190.91%-224K | -903.47%-1.45M | -1,441.33%-1.01M |
| Operating profit | 105.76%600K | 60.94%-4.13M | 44.47%-5.67M | 38.30%-38.1M | 32.09%-6.88M | 26.55%-10.42M | 87.06%-10.58M | 5.07%-10.21M | -50.06%-61.74M | 65.80%-10.13M |
| Net non-operating interest income (expenses) | -44.46%-1.26M | 21.56%-1.27M | 1.84%-1.02M | -64.81%-5.49M | -138.38%-1.97M | 76.58%-875K | -268.83%-1.61M | -479.12%-1.04M | -158.57%-3.33M | 25.72%-826K |
| Non-operating interest expense | 44.46%1.26M | -21.56%1.27M | ---- | 64.81%5.49M | 138.38%1.97M | -76.58%875K | --1.61M | ---- | 158.57%3.33M | -25.72%826K |
| Total other finance cost | ---- | ---- | -1.84%1.02M | ---- | ---- | ---- | 268.83%1.61M | 479.12%1.04M | ---- | ---- |
| Other net income (expenses) | 117.08%729K | -23.39%-2.03M | -333.60%-1.1M | 95.74%-5.81M | 101.38%358K | 70.65%-4.27M | 96.09%-1.65M | -108.70%-253K | -518.39%-136.32M | -902.86%-25.96M |
| Gain on sale of security | 295.59%399K | -701.11%-1.63M | -152.84%-288K | 121.88%2.05M | 176.26%1.44M | 70.13%-204K | 121.11%271K | 109.89%545K | 43.10%-9.36M | -186.93%-1.88M |
| Special income (charges) | --0 | --0 | ---- | 93.06%-8.18M | 98.39%-352K | 43.78%-4.9M | 97.23%-1.08M | --0 | -109,287.04%-117.92M | -580.29%-21.88M |
| -Less:Restructuring and mergern&acquisition | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Less:Impairment of capital assets | --0 | --0 | ---- | -93.48%1.94M | -98.66%352K | --504K | -68.06%1.08M | ---- | --29.73M | --26.34M |
| -Less:Write off | --0 | ---- | ---- | -23.40%6.24M | --0 | -33.86%4.4M | ---- | ---- | --8.15M | --1.5M |
| -Gain on sale of business | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | -2,546.33%-80.04M | --0 |
| Other non-operating income (expenses) | -60.57%330K | -125.17%-402K | -152.81%-809K | 160.01%1.39M | -116.05%-726K | 116.29%837K | 279.64%1.6M | 60.40%-320K | -1,536.65%-2.31M | 1,592.74%4.52M |
| Income before tax | 100.42%65K | 46.32%-7.43M | 32.31%-7.78M | 75.47%-49.4M | 77.00%-8.49M | 52.05%-15.57M | 88.74%-13.84M | -51.81%-11.5M | -212.35%-201.4M | -10.78%-36.92M |
| Income tax | 1,046.67%516K | 523.46%2.06M | -10,994.12%-1.89M | 175.12%6.47M | 425.63%6.92M | 102.37%45K | 91.01%-486K | -102.06%-17K | -159.26%-8.61M | -124.69%-2.13M |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 97.11%-451K | 28.96%-9.49M | 48.64%-5.9M | 71.02%-55.86M | 55.70%-15.42M | 48.93%-15.61M | 88.64%-13.36M | -36.68%-11.48M | -144.04%-192.79M | 17.03%-34.8M |
| Net income continuous operations | 97.11%-451K | 28.96%-9.49M | 48.64%-5.9M | 71.02%-55.86M | 55.70%-15.42M | 48.93%-15.61M | 88.64%-13.36M | -36.68%-11.48M | -144.04%-192.79M | 17.03%-34.8M |
| Noncontrolling interests | 50.69%-2.84M | 8.16%-2.5M | 28.91%-2.91M | -27.29%-12.97M | 92.03%-391K | -511.13%-5.76M | 51.51%-2.72M | -281.38%-4.1M | 2.28%-10.19M | -2,482.11%-4.91M |
| Net income attributable to the company | 124.28%2.39M | 34.29%-6.99M | 59.58%-2.99M | 76.51%-42.89M | 49.74%-15.03M | 69.20%-9.85M | 90.50%-10.63M | -0.81%-7.39M | -166.30%-182.6M | 28.41%-29.89M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | -186.70%-12.97M | 6.61M | -8.91M | -1,203.93%-5.9M | -414.44%-5.84M | 63.56%-4.53M | ||||
| Net income attributable to common stockholders | 354.09%2.39M | 34.29%-6.99M | 59.58%-2.99M | 75.91%-42.89M | -36.44%-34.61M | 97.06%-941K | 90.54%-10.63M | -19.31%-7.39M | -217.12%-178.07M | 35.26%-25.37M |
| Diluted earnings per share | 200.00%0.01 | 0.00%-0.04 | 77.78%-0.02 | 88.69%-0.31 | 35.14%-0.24 | 97.92%-0.01 | 97.70%-0.04 | 10.00%-0.09 | -207.87%-2.74 | 40.32%-0.37 |
| Basic earnings per share | 200.00%0.01 | 0.00%-0.04 | 77.78%-0.02 | 88.69%-0.31 | 35.14%-0.24 | 97.92%-0.01 | 97.70%-0.04 | 10.00%-0.09 | -207.87%-2.74 | 40.32%-0.37 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.